|Iggy Kass, Waters||Waters UPLC/MS Introduction|
|Bill Schaefer, Merck||Application of Ultra-High Performance Liquid Chromatography (UPLC) Methods to LC-MS-Based Metabolomics Profiling|
|Gary Siuzdak, Scripps||A Metabolomics Platform: from Discovery to Diagnosis|
Bill Schaefer Application of Ultra-High Performance Liquid Chromatography (UPLC) Methods to LC-MS-Based Metabolomics Profiling
Gary Siuzdak Mass spectrometry is an established technology in protein and drug analysis and is now expanding into endogenous metabolite research. Its utility derives from its wide dynamic range, reproducible quantitative analysis, and the ability to analyze biofluids with extreme molecular complexity. The aims of our further developing mass spectrometry for proteomics and metabolomics range from understanding basic biochemistry to biomarker discovery and the structural characterization of physiologically important metabolites. In this presentation I will discuss our evolution in mass-based approaches for proteomics and endogenous metabolite analysis toward biomarker discovery and understanding fundamental biochemistry.
Bill Schaefer - Bill is currently the Director of Analytical Investigative Toxicology in Safety Assessment at Merck. He received a BS degree in Chemistry from Indiana University of Pennsylvania and a PhD in Biochemistry from Vanderbilt University studying under Dr. Fred Guengerich in the Center in Molecular Toxicology. His keen interest in the application of analytical instrumentation to biochemical problems led him to work as a post-doctoral fellow with Dr. Ian Blair and Dr. Martin Waterson focusing on protein structure determinations using mass spectrometry, as well as conventional protein sequencing techniques. In 1987 Bill joined SmithKline (and French) in the Department of Drug Metabolism where he was involved with many aspects of drug disposition, especially applications of mass spectrometry to quantitative methods and structure elucidation. In 1998, he moved to the Biochemical and Investigative Toxicology group in Safety Assessment at Merck. Bill's current group is focused on the application of analytical biochemistry techniques and the development of metabolomics and proteomics technologies to support investigative toxicology.
Gary Siuzdak, B.S. in Chemistry and B.A. in Mathematics, Rhode Island College; Ph.D. in Physical Chemistry, Dartmouth College. Gary is currently the Senior Director of the Center for Mass Spectrometry, Associate Professor of Molecular Biology at The Scripps Research Institute in La Jolla, California (http://masspec.scripps.edu/) and Visiting Faculty at Lawrence Berkeley National Laboratory.
His research includes the development of nanostructure-initiated desorption/ionization, intact viral analysis, preparative mass spectrometry, mass-based inhibitor-enzyme screening and, most recently, novel approaches to metabolomics. He has over 130 peer-reviewed publications and three books, the latest being The Expanding Role of Mass Spectrometry in Biotechnology, 2nd Edition 2006. Gary also established and maintains a website dedicated to the history of mass spectrometry (http://masspec.scripps.edu/information/history/).
This page has been accessed
times since 9/15 /96 .
Last Updated 2/25/2007